Sentences with phrase «as olaparib»

HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib.

One, known as Olaparib, was identified and developed at KuDOS Pharmaceuticals and subsequently at AstraZeneca, and is being tested at the ICR.

Based on these studies, the authors are designing a clinical trial to test whether DNA repair inhibitors, such as olaparib, are active against IDH1 - and IDH2 - mutant tumors.

PARP (Poly ADP - Ribose Polymerase) inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.

«This suggests that PGAM1 inhibitors can sensitize cancers to PARP inhibitors such as Olaparib, thereby expanding the benefits of PARP inhibitors to BRCA1 / 2 - proficient cancers, particularly triple - negative breast cancers that currently lack effective therapies,» says author Min Huang.

Clinicians are currently worried that breast cancer patients with low or absent BRCA1 may become resistant to therapeutic agents such as Olaparib.

Not exact matches

Olaparib is good at killing cancer cells that have errors in genes that have a role in repairing damaged DNA such as BRCA1 or BRCA2.

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

An anti-angiogenic agent, or blood vessel inhibitor, called cediranib (which inhibits a protein known as VEGFR) and olaparib, a PARP inhibitor, are each clinically active in recurrent ovarian cancer.

As of March 2014, median progression - free survival was 9.2 months for olaparib and 16.7 months for the combination therapy, which is a significant advantage.